Skip directly to site content Skip directly to page options Skip directly to A-Z link


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
														Search
		×
			NIOSH
			NIOSH
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


The National Institute for Occupational Safety and Health (NIOSH)


Facebook
        Twitter
        LinkedIn
        Syndicate





N-ETHYLMORPHOLINE								Related Pages
										*OSHA comments from the January 19, 1989 Final Rule on Air Contaminants Project extracted from 54FR2332 et. seq. This rule was remanded by the U.S. Circuit Court of Appeals and the limits are not currently in force.*
**CAS:** 100-74-3; **Chemical Formula:** C6H13NO
OSHA’s former 8-hour TWA PEL for N-ethylmorpholine was 20 ppm, with a skin notation. The proposed permissible exposure limit was 5 ppm as an 8-hour TWA, also with a skin notation, and the final rule establishes this limit and retains the skin notation, which is consistent with the limits of the ACGIH. NIOSH (Ex. 8-47, Table N1) agrees with the selection of this limit. N-Ethylmorpholine is a colorless, flammable liquid with an ammonia-like odor; this substance is a severe eye irritant.
Prolonged exposure to fairly low concentrations of this substance causes corneal edema, blue-gray vision, and colored haloes. Typically, vision becomes misty and haloes appear a few hours after workers have been exposed to the vapors for a period of hours. Distortion of vision can occur even at levels considerably lower than those that cause irritation (Mastromatteo 1965/Ex. 1-146).
Reversible corneal edema has been observed in workers exposed to 40 ppm or more of N-ethylmorpholine for several hours (Dernehl 1966a/Ex. 1-62). Workers routinely exposed to 3- to 4-ppm concentrations but never to concentrations above 11 ppm complained of haloes and foggy vision as well as drowsiness (ACGIH 1986/Ex. 1-3, p. 263). The irritant effects of N-ethylmorpholine were also seen in a controlled-exposure experiment on volunteer subjects. Ten subjects exposed for 2.5 minutes to a concentration of 100 ppm experienced irritation of the eyes, nose, and throat; those exposed for 2.5 minutes to 50 ppm experienced slight irritation; and no irritation was reported after exposure for 2.5 minutes to 25 ppm (ACGIH 1986/Ex. 1-3, p. 263). N-ethylmorpholine is also readily absorbed through the skin (Smyth, Carpenter, Weil, and Pozzani 1954/Ex. 1-440).
OSHA’s former 20-ppm PEL for N-ethylmorpholine did not protect exposed workers against the occurrence of corneal edema. Because corneal edema is painless as it is developing and symptoms have a delayed onset, workers are especially likely not to be aware of the danger of exposure. This is particularly hazardous because the effects on visual function of repeatedly exposing the eyes to substances that cause corneal edema are not known. The Agency received no comments on the health effects or revised exposure limits for N-ethylmorpholine, with the exception of NIOSH’s submission.
OSHA concludes that reducing the PEL to 5 ppm as an 8-hour TWA (and retaining the skin notation) is necessary to protect occupationally exposed workers from ethylmorpholine’s injurious ocular effects. The new, lower PEL will reduce the significant risk of material health impairment, which is manifested as corneal edema, visual distortion, and impaired vision, that is associated with exposure to this substance at concentrations above the revised PEL.
										
							
								Page last reviewed:  September 28, 2011						Content source:  	National Institute for Occupational Safety and Health NIOSH
1988 OSHA PEL Project Documentation
Index of Chemical Names
Index of CAS Numbers Follow NIOSH Facebook
Pinterest
Twitter
YouTube
 NIOSH Homepage NIOSH A-Z
Workplace Safety & Health Topics
Publications and Products
Programs
Contact NIOSH


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue